Stocktoria

Eurofins Scientific SE ERF.PA

FR · Euronext Paris · XPAR · stock · Healthcare · website

Eurofins Scientific SE (ERF.PA) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the grey zone. It pays a dividend yielding 0.91% (safety: safe). FY2025 revenue was €7.3B at a 6.5% net margin.

Chart by TradingView
7/9
Piotroski F — financial health
2.28
Altman Z″ — distress risk · grey
22.7%
Dividend payout · safe
€68.46 as of 2026-07-01 · +1.7% 1y
€58.64€68.5652-wk
Market cap USD$13.5B
P / E25×
Net margin6.5%
Beta0.85
Employees65,694

Analyst price target

€71.03 +3.8% vs last
consensus: buy · 14 analysts
range €48.00 – €86.00

Wall Street analyst consensus — a sentiment gauge, not our scoring.

About Eurofins Scientific SE

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services. In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing. Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.

Revenue trend · last 4y · up

How it ranks in Healthcare · percentile among 73 companies

Piotroski Fstronger than 58%
Net marginstronger than 25%
Return on equitystronger than 42%
Revenue growthstronger than 48%

Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 7/9 tests passed

Altman Z″ components · grey zone

ComponentValue
Working capital / assets0.02
Retained earnings / assets0.275
EBIT / assets0.074
Equity / liabilities0.709

FAQ

Is ERF.PA financially healthy?

Eurofins Scientific SE's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.

Does ERF.PA pay a dividend, and is it safe?

Yes. Eurofins Scientific SE pays a dividend yielding about 0.91% with a 22.7% payout ratio, rated “safe” for safety.

How profitable is ERF.PA?

In FY2025, Eurofins Scientific SE had a net margin of 6.5% and a return on equity of 10.5%.

Computed from company filings · FR · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.